Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker

Rhea-AI Filing Summary

Zevra Therapeutics’ affiliate reports planned stock sales by an insider. A Form 144 notice lists up to 42,666 shares of common stock held in an account at Morgan Stanley Smith Barney LLC Executive Financial Services for potential sale on NASDAQ as of August 14, 2026.

The shares relate to restricted stock units granted on June 21, 2025 by the issuer. The notice also references prior Rule 10b5-1 sales for Rahsaan Thompson, including 34,557 common shares sold for $438,303.71 on June 22, 2026.

Key Figures

Shares subject to potential sale: 42,666 shares Planned market: NASDAQ Grant date of RSUs: 06/21/2025 +3 more

6 metrics

Shares subject to potential sale 42,666 shares Common stock held at Morgan Stanley Smith Barney LLC Executive Financial Services

Planned market NASDAQ Listed as the market for the potential sale of common shares

Grant date of RSUs 06/21/2025 Restricted Stock Units from issuer underlying the shares

Recent shares sold under 10b5-1 34,557 shares Rule 10b5-1 sales for Rahsaan Thompson on 06/22/2026

Proceeds from recent 10b5-1 sale $438,303.71 Value of 34,557 common shares sold on 06/22/2026

Notice date reference 08/14/2026 Date associated with the proposed sale notice

Key Terms

Restricted Stock Units, 10b5-1 Sales, Executive Financial Services

3 terms

Restricted Stock Units financial

"Common | 06/21/2025 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 Sales regulatory

"10b5-1 Sales for RAHSAAN THOMPSON 101 Federal Street"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

What does Zevra Therapeutics (ZVRA) disclose in this Form 144 filing?

The filing reports a proposed sale of up to 42,666 common shares held at Morgan Stanley Smith Barney LLC, linked to restricted stock units granted June 21, 2025, with potential sales on NASDAQ after August 14, 2026.

How many ZVRA shares are covered by the new sale notice?

The notice covers up to 42,666 shares of Zevra Therapeutics common stock. These shares are associated with restricted stock units granted on June 21, 2025, and may be sold through Morgan Stanley Smith Barney LLC on NASDAQ.

What prior ZVRA stock sales are referenced in the past three months?

The filing references Rule 10b5-1 sales of 34,557 ZVRA common shares for $438,303.71 on June 22, 2026, for Rahsaan Thompson, providing context for recent trading activity under a pre-arranged plan.

Who is the broker involved in the potential Zevra Therapeutics share sale?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services at 1 New York Plaza, 8th Floor, New York, NY 10004, which would handle potential NASDAQ sales of the 42,666 common shares covered by this notice.

What type of equity award underlies the ZVRA shares in this Form 144?

The shares are tied to Restricted Stock Units granted on June 21, 2025 by the issuer. These RSUs represent equity compensation that has resulted in common shares eligible for potential public resale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:35 PM Accepted by SEC EDGAR 08/14/2026 - 04:31 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	42666	477005.88	59383781	08/14/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/21/2025	Restricted Stock Units	Issuer			42666	06/21/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for RAHSAAN THOMPSON 101 Federal Street Boston MA 02110	Common	06/22/2026	34557	438303.71

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)